Clinical Trials

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

100 enrolled

Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

140 enrolled 32 charts

Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

297 enrolled

Breast Neoplasms

NCT05693766 2026-01-20

INSIGHT

64 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT04721977 2026-01-09

MK-7119-001

66 enrolled 7 charts

Breast Neoplasms

NCT06105684 2026-01-07

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

40 enrolled

Breast Neoplasms

NCT06085742 2025-12-19

BRE-08

25 enrolled

Breast Neoplasms

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

22 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06764940 2025-11-28

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

120 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06525766 2025-10-03

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

35 enrolled

Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

17 enrolled 16 charts

Breast Neoplasms, Meningeal Neoplasms

NCT07019337 2025-06-13

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

100 enrolled

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

411 enrolled

Breast Neoplasms

NCT04296162 2025-04-17

ORCHID

178 enrolled

Breast Neoplasms

NCT04768426 2025-03-20

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06787339 2025-01-22

Calorite

198 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT03872388 2024-10-02

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

6 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06598046 2024-09-19

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

48 enrolled

Breast Neoplasms

NCT06483386 2024-07-03

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

109 enrolled

Breast Neoplasms

NCT05163223 2024-06-17

Cornerstone001

10 enrolled

Breast Neoplasms

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

152 enrolled 14 charts

Breast Neoplasms

NCT04383275 2024-03-22

IRIS

356 enrolled

Breast Neoplasms

NCT02954055 2024-02-26

METEORA-II

140 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03818685 2024-02-12

BreastImmune03

95 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

182 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01387295 2023-12-11

Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

38 enrolled 11 charts

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

3 enrolled 6 charts

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

612 enrolled 30 charts 2 FDA

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

77 enrolled 9 charts

Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT04942899 2023-03-01

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

70 enrolled

Breast Neoplasms

NCT05747326 2023-02-28

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

30 enrolled

Breast Neoplasms

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

6 enrolled 8 charts

Breast Neoplasms

NCT04001621 2022-12-08

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

100 enrolled

Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

73 enrolled

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast Neoplasms

NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Phase 2 Suspended

170 enrolled